logo
logo
Ascendis Pharma A/S

Ascendis Pharma A/S

NASDAQ•ASND
CEO: Mr. Jan Moller Mikkelsen
セクター: Healthcare
業種: Biotechnology
上場日: 2015-01-28
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
連絡先情報
Tuborg Boulevard 12, Hellerup, 2900, Denmark
45-70-22-22-44
ascendispharma.com
時価総額
$13.28B
PER (TTM)
-49.1
34.3
配当利回り
--
52週高値
$242.00
52週安値
$124.06
52週レンジ
78%
順位55Top 80.0%
2.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$285.45M+0.00%
直近4四半期の推移

EPS

-$0.63+0.00%
直近4四半期の推移

フリーCF

$78.44M+0.00%
直近4四半期の推移

2024 Annual 決算ハイライト

主なハイライト

Strong Revenue Growth Driven by Licensing Total revenue reached 363.6M EUR, up 96.9M EUR, primarily due to the 100.0M USD upfront payment from the Novo Nordisk license agreement.
YORVIPATH FDA Approval and Launch YORVIPATH received FDA approval and launched commercially in the US for adult hypoparathyroidism, contributing 28.7M EUR in revenue.
Operating Loss Significantly Reduced Operating loss improved by 176.8M EUR to (278.8M EUR), benefiting from increased revenue and lower research and development costs.
TransCon CNP Achondroplasia Data Positive Pivotal ApproaCH trial showed TransCon CNP achieved superior annualized growth velocity versus placebo in children with achondroplasia.

リスク要因

Negative Equity and Future Financing Need Total equity remains negative at (105.7M EUR); future viability depends on obtaining additional capital on acceptable terms to fund operations.
Reliance on Single-Source Suppliers Loss or failure of single-source suppliers for parent drugs and components could materially and adversely affect business and supply chain.
Clinical Development Delays and Failure Clinical trials are lengthy and expensive with uncertain outcomes; delays or failure to obtain regulatory approval would substantially harm business.
Geopolitical Conflicts Disrupt Operations Conflicts like Russia/Ukraine and Israel/Hamas could adversely impact clinical trials, supply chain operations, regulatory timelines, and commercial activities.

見通し

SKYTROFA Adult GHD Expansion sBLA submitted to FDA for SKYTROFA in adult GHD; PDUFA goal date is July 27, 2025, expanding market opportunity for TransCon hGH.
TransCon CNP Regulatory Submissions Planned NDA submission for TransCon CNP in pediatric achondroplasia planned for Q1 2025 (FDA), followed by MAA submission in Q3 2025 (EMA).
Novo Nordisk Collaboration Potential Exclusive worldwide license granted to Novo Nordisk for TransCon platform in metabolic and cardiovascular diseases, including 285M USD milestones.
Adequate Cash Runway Maintained Cash and cash equivalents totaled 559.5M EUR; expected to fund operations for at least the next twelve months based on current plan.

同業比較

売上高 (TTM)

Baxter International Inc.BAX
$11.24B
+5.7%
Royalty Pharma plcRPRX
$2.38B
+5.1%
Moderna, Inc.MRNA
$1.94B
-39.3%

粗利益率 (最新四半期)

Ionis Pharmaceuticals, Inc.IONS
98.5%
-0.7pp
BridgeBio Pharma, Inc.BBIO
94.6%
+16.5pp
Madrigal Pharmaceuticals, Inc.MDGL
93.7%
-2.8pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
RPRX$19.36B25.210.6%0.0%
ROIV$18.93B-22.8-18.3%4.0%
RVMD$18.62B-19.0-49.2%7.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
39.0%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年4月29日
|
EPS:-
|
売上高:-
財務レポート
財務データ
全年度

  • Form 20-F - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月12日|
    売上高: $393.38M+36.3%
    |
    EPS: $-7.06+23.6%
    予想を下回る

  • Form 20-F - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月7日|
    売上高: $288.50M+421.2%
    |
    EPS: $-9.25+17.8%
    予想を下回る

  • Form 20-F - FY 2022

    会計期末: 2022年12月31日|提出日: 2023年2月16日|
    売上高: $288.50M+557.9%
    |
    EPS: $-9.25-48.6%
    予想を下回る

  • Form 20-F - FY 2021

    会計期末: 2021年12月31日|提出日: 2022年3月2日|
    売上高: $288.50M+11.9%
    |
    EPS: $-9.25+15.5%
    予想を上回る

  • Form 20-F - FY 2020

    会計期末: 2020年12月31日|提出日: 2021年3月10日|
    売上高: $288.50M-48.0%
    |
    EPS: $-9.25-76.5%
    予想を下回る